A Novel, Circulating Tumor Cell Enrichment Method Reduces ARv7 False Positivity in Patients with Castration-Resistant Prostate Cancer
Authors:
- Takehiko NakasatoTNTakehiko Nakasato
- Chiho KusakaCKChiho Kusaka
- Mika OtaMOMika Ota
- Yuki HasebeYHYuki Hasebe
- Kumiko UedaKUKumiko Ueda
- Tsutomu UnokiTUTsutomu Unoki
- Kazuhiko OshinomiKOKazuhiko Oshinomi
- Jun MoritaJMJun Morita
- Yoshiko MaedaYMYoshiko Maeda
- Takeshi ShichijoTSTakeshi Shichijo
- Michio NaoeMNMichio Naoe
- Yoshio OgawaYOYoshio Ogawa
Open Access
- 11 March 2020
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 10 (3) , 151
Abstract
Background: The AR-V7 splice variant is a cause of castration-resistant prostate cancer (CRPC). However, testing for the presence of AR-V7 by real-time polymerase chain reaction (RT-PCR) shows AR-V7 positivity in healthy individuals. We hypothesized that the positivity reflects contamination by hematopoietic cells. We tried a novel circulating tumor cell (CTC) enrichment instrument, using Celsee, to clear hematopoietic cells. Methods: We tested whole blood or Celsee-enriched samples for AR-V7 by RT-PCR, and included samples from 41 CRPC patients undergoing sequential therapy. We evaluated the associations between AR-V7 status and clinical factors. We evaluated factors affecting AR-V7 positivity. Results: AR-V7 positivity was lower in Celsee-enriched than in whole blood specimens. AR-V7 and clinical factors did not predict the therapy effectiveness. We found no significant differences in the effectiveness of enzalutamide/abiraterone (Enz/Abi) upon AR-V7 evaluation. All AR-V7 positive patients had resistance to Enz/Abi. Docetaxel (DTX), cabazitaxel (CBZ), and Radium223 treatment showed no significant difference in the treatment effectiveness, regardless of AR-V7 presence. AR-V7 was more frequently positive than Extent of disease (EOD) 2 in cases with bone metastases. Conclusion: Celsee CTC enrichment suppresses AR-V7 false positivity. All AR-V7 positive patients presented resistance to Enz/Abi. DTX, CBZ, and Radium223 were effective and remain treatment options. AR-V7 positivity should progressively appear in patients with advanced bone metastases.Keywords
All Related Versions
This publication has 23 references indexed in Scilit:
- Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate CancerEuropean Urology, 2017
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3Journal of Clinical Oncology, 2016
- Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood SamplesPLOS ONE, 2016
- Serial blood-based analysis of AR-V7 in men with advanced prostate cancerAnnals of Oncology, 2015
- Mechanisms of resistance in castration-resistant prostate cancer (CRPC)2015
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate CancerNew England Journal of Medicine, 2014
- Challenges in circulating tumour cell researchNature Reviews Cancer, 2014
- Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate CancerCancer Research, 2012
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone DrivenJournal of Clinical Oncology, 2008
- Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancerBritish Journal of Cancer, 2004